Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jose Baez

Internal Medicine Lawrence, MA Doctor of Osteopathy

NPI 1336103233 CMS profile 60728

25 Marston St, Suite 105, Lawrence, MA 01841

Open in the dashboard

General payments

$31,729

1,634 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jose Baez of Lawrence, MA is reported in the CMS Open Payments database as having received $31,729 across 1,634 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,684 252
2024 General $3,694 168
2023 General $4,212 209
2022 General $4,330 239
2021 General $4,904 267
2020 General $3,407 193
2019 General $5,497 306

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jose Baez
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Jose Baez were reported at $5,684. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Jose Baez Internal Medicine median Middle half National median
2019 $5,497 $159 $48–$570 $163
2020 $3,407 $119 $33–$402 $114
2021 $4,904 $135 $37–$521 $132
2022 $4,330 $141 $42–$496 $149
2023 $4,212 $149 $45–$519 $160
2024 $3,694 $154 $47–$537 $164
2025 $5,684 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $5,655 246 payments
  2. AbbVie, Inc. $4,980 294 payments
  3. Novo Nordisk Inc $1,598 92 payments
  4. GlaxoSmithKline, LLC. $1,442 90 payments
  5. Lilly USA, LLC $1,355 80 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $1,337 51 payments
  7. Amgen Inc. $1,326 65 payments
  8. Astellas Pharma US Inc $1,205 44 payments
  9. Merck Sharp & Dohme Corporation $1,132 56 payments
  10. Pfizer Inc. $1,129 73 payments
  11. Other $10,570 543 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $31,452 1,615 payments
  2. Education $277 19 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $2,806 117 payments
  2. LINZESS $1,947 125 payments
  3. CREON $1,600 92 payments
  4. BREZTRI $1,354 48 payments
  5. TRELEGY ELLIPTA $1,269 81 payments
  6. RYBELSUS $1,032 68 payments
  7. UBRELVY $1,026 54 payments
  8. VRAYLAR Neuroscience $1,026 58 payments
  9. JARDIANCE $856 53 payments
  10. VRAYLAR Neuroscience $848 44 payments
  11. Other $25,905 1,396 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 211 drugs

Part D claims

38,314

Median for Internal Medicine: 777

Drug cost

$5,140,646

Median for Internal Medicine: $73,373

Branded share of claims

32%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 1,472 $947,742
Trulicity Dulaglutide Brand 683 $696,058
Januvia Sitagliptin Phosphate Brand 825 $508,676
Linzess Linaclotide Brand 550 $335,308
Myrbetriq Mirabegron Brand 509 $243,945
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 332 $221,899
Ozempic Semaglutide Brand 135 $159,385
Eliquis Apixaban Brand 247 $159,312
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 244 $156,597
Jardiance Empagliflozin Brand 167 $123,315

The 10 drugs with the highest cost, of 211 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$108,154

Medicare's payments for the services billed

Medicare patients

202

Average age 66

Services billed

2,591

121 women, 81 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Diabetes 51%
Depression 44%
Chronic kidney disease 41%
Arthritis 35%
Osteoporosis 21%
Ischemic heart disease 12%
COPD 12%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 36 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
$377 1,472 —
LINZESS
$377 550 —
BREZTRI
$281 244 —
CREON
$225 68 —
GEMTESA
$197 62 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 36 with Patron

Records

1,634 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record